Watch for FDA acceptance of the Phase 2 protocol and initiation of the Phase 2 trial in Q1 2027. The open-label stabilization data is encouraging but preliminary; blinded placebo-controlled Phase 2 results will be the next major catalyst.
Price Chart
Executive Summary
Gain Therapeutics announced long-term open-label extension data from its Phase 1b study of rexaceract in Parkinson's disease, showing stabilization of MDS-UPDRS motor scores over 12 months in 12 evaluable patients. The company plans to submit a Phase 2 protocol to the FDA in the coming weeks and initiate a Phase 2 trial in Q1 2027. The data is preliminary and open-label, but supports the disease-modifying potential of rexaceract.
Key Facts
- 12 of 13 evaluable patients completed 12 months of rexaceract dosing in the open-label extension as of August 31, 2026.
- MDS-UPDRS motor scores (Parts II and III) were stable over 12 months, with no clinically meaningful progression (vs. ~6-point expected annual increase in early PD).
- No new safety signals observed; lower incidence of treatment-emergent adverse events in the 9-month extension vs. initial 3-month dosing.
- Company expects to submit a Phase 2 study protocol to the FDA in the coming weeks and initiate the Phase 2 trial in Q1 2027.
- Participants with both high and low baseline CSF GluSph levels showed stabilization of motor scores over 12 months.
Financial Impact
No financial figures reported. The filing is a clinical data update with no revenue, earnings, or deal values disclosed.
Risk Factors
- Open-label data is preliminary and may not predict blinded Phase 2 results.
- Phase 2 protocol may not be accepted by the FDA as designed.
- Small sample size (12 evaluable patients) limits statistical reliability.
- Company is pre-revenue with no approved products; dependent on future financing for Phase 2 execution.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-112624 |
| Document: 0001104659-26-112624-index-headers.html | 0001104659-26-112624 |
| Document: 0001104659-26-112624-index.html | 0001104659-26-112624 |
| Document: 0001104659-26-112624.txt | 0001104659-26-112624 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | Press Release | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.17 (−31.98%) |
Oct 1, 2026 26d ago | 8-K | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.17 (−31.98%) |
Aug 11, 2026 11w ago | Press Release | $2.06 $2.03 | ▼ −1.46% | ▼ −1.05% | $1.17 (−43.20%) |
Jul 16, 2026 14w ago | 8-K | $1.66 $1.82 | ▲ +9.64% | ▲ +11.31% | $1.17 (−29.52%) |
Jun 29, 2026 17w ago | 8-K | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.17 (−42.36%) |
Jun 29, 2026 17w ago | Press Release | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.17 (−42.36%) |
May 26, 2026 22w ago | 8-K | $1.82 $1.96 | ▲ +7.69% | ▲ +6.61% | $1.17 (−35.71%) |
May 11, 2026 24w ago | Press Release | $1.82 $1.62 | ▼ −10.99% | ▼ −10.90% | $1.17 (−35.71%) |
Apr 28, 2026 26w ago | DEFA14A | $1.76 $1.91 | ▲ +8.52% | ▲ +5.41% | $1.17 (−33.52%) |
Mar 26, 2026 30w ago | Press Release | $1.89 $1.85 | ▼ −2.12% | ▼ −3.75% | $1.17 (−38.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers